Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4534MR)

This product GTTS-WQ4534MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4534MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ513MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ12589MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ13348MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ9866MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ5987MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ14211MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ13240MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ5078MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW